Home › Research › Biomarkers
Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)
Susanne G. Mueller, Michael Walter Weiner, Leon J. Thal, Ronald Carl Petersen, Clifford R. Jack, William J. Jagust, John Q. Trojanowski, Arthur W. Toga, Laurel A. Beckett. Alzheimer s & Dementia, 2005-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
With the increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over the last years about the pathomechanisms involved in AD allow for the development of specific treatment strategies aimed at slowing down or even preventing neuronal death in AD. However, this requires also that (1) AD can be diagnosed with high accuracy, because non-AD dementias would not benefit from an AD-specific treatment; (2) AD can be diagnosed in very early stages when any intervention would be most effective; and (3) treatment efficacy can be reliably and meaningfully monitored. Although there currently is no ideal biomarker that would fulfill all these requirements, there is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is exploring which combinations of these biomarkers are the most powerful for diagnosis of AD and monitoring of treatment effects.
What this study adds
Evidence grade: Not rated
Argues that earlier and more accurate Alzheimer's diagnosis may come from combining imaging, spinal fluid and blood biomarkers. It describes the Alzheimer's Disease Neuroimaging Initiative (ADNI) as exploring which combinations work best for diagnosis and for tracking treatment effects.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., et al. (2005). Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2005.06.003
Vancouver
Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust WJ, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer s & Dementia. 2005. doi:10.1016/j.jalz.2005.06.003. PMID: 17476317.
BibTeX
@article{mueller2005-17476317,
author = {Mueller, Susanne G. and Weiner, Michael Walter and Thal, Leon J. and Petersen, Ronald Carl and Jack, Clifford R. and Jagust, William J. and Trojanowski, John Q. and Toga, Arthur W. and Beckett, Laurel A.},
title = {{Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)}},
journal = {Alzheimer s \& Dementia},
year = {2005},
doi = {10.1016/j.jalz.2005.06.003},
pmid = {17476317},
url = {https://doi.org/10.1016/j.jalz.2005.06.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Why it matters
Argues that earlier and more accurate Alzheimer's diagnosis may come from combining imaging, spinal fluid and blood biomarkers. It describes the Alzheimer's Disease Neuroimaging Initiative (ADNI) as exploring which combinations work best for diagnosis and for tracking treatment effects.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 51 of the 95 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,240 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 53.9 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 3 / 6 | Cited 6.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 260 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Laurel A. Beckett: h-index 116 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17476317) |
| Free to read | 2 / 2 | Free to read |
| Points | 51 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 95 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also in Biomarkers
136 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.